This summer, the FDA approved a drug for the treatment of seizures associated with Dravet syndrome, a rare form of epilepsy. The approval comes after years of clinical trials, two of which took place in the CCTSI's CTRC at Children's Hospital Colorado.
CCTSI pilot programs foster knowledge and discovery. Notable among the projects funded this year are three CU-CSU awards that will support new collaborations between researchers from both universities.
A leader in clinical research, Flaig is associate dean for clinical research at the University of Colorado and serves on the executive committee for the CCTSI. He also directs the CCTSI's new Trial Innovation Network Hub Liaison Team of the CTSA program.
For any researcher, it’s not enough to simply amass data. That’s akin to hauling piles of dirt and rock from the earth and walking away. Just as the art of refining ore lies in extracting usable metal from raw ore, careful research requires a plan to mine reservoirs of data for the nuggets that reveal patterns and increase our understanding of the world.
Dr. Joaquin Espinosa, professor of pharmacology in the CU School of Medicine is the force behind a strategic and coordinated effort to bring $16.5 million in grant funding to CU for Down syndrome research.